{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T10:39:28Z","timestamp":1722854368836},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BCTT"],"DOI":"10.2147\/bctt.s16774","type":"journal-article","created":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:39:31Z","timestamp":1467247171000},"page":"1-7","source":"Crossref","is-referenced-by-count":2,"title":["Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer"],"prefix":"10.2147","volume":"Volume 3","author":[{"given":"Allan","family":"Lipton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2011,3]]},"container-title":["Breast Cancer: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=9259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:02:56Z","timestamp":1477864976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/bones-breasts-and-bisphosphonates-rationale-for-the-use-of-zoledronic--peer-reviewed-article-BCTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/bctt.s16774","relation":{},"ISSN":["1179-1314"],"issn-type":[{"value":"1179-1314","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}